Ken Griffin Opiant Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023
BUY
$9.38 - $20.29 $132,905 - $287,489
14,169 New
14,169 $287,000
Q1 2021

May 17, 2021
SELL
$8.2 - $14.49 $12,504 - $22,097
-1,525 Reduced 12.07%
11,110 $118,000
Q4 2020

Feb 16, 2021
BUY
$6.87 - $8.88 $86,802 - $112,198
12,635 New
12,635 $102,000

Others Institutions Holding OPNT

# of Institutions
2
Shares Held
300
Call Options Held
0
Put Options Held
0
View Full List

About OPIANT PHARMACEUTICALS, INC.

OPNT Quotes by TradingView
  • Ticker OPNT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,164,150
  • Description
  • Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overd...
More about OPNT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email